CSL strikes US$1.6 billion licensing deal for rare disease drug CSL Limited (ASX:CSL) has secured a...

CSL strikes US$1.6 billion licensing deal for rare disease drug CSL Limited (ASX:CSL) has secured an exclusive licensing agreement with Swiss biotechnology company Alentis Therapeutics to develop and commercialise lixudebart, an experimental treatment targeting rare kidney and liver diseases. The deal gives CSL rights to advance the drug, which is currently in Phase 2 trials for ANCA-associated vasculitis, a rare autoimmune disease that can cause severe kidney damage.